Streetbeat News

Products Services

OXY

Occidental Low Carbon Ventures (OLCV), a subsidiary of Occidental (NYSE:OXY), and TAE Technologies have signed a memorandum of understanding to explore using TAE's fusion technology for emissions-free power and heat in Direct Air Capture (DAC) facilities.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:28 pm

PCSA

Processa Pharmaceuticals shares are trading higher following the announcement of positive efficacy results from a preliminary evaluation of its Phase 1b dose-escalating trial with NGC-Cap in gastrointestinal cancer.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:27 pm

CRVO

CervoMed Inc. (NASDAQ:CRVO) has completed enrollment in its Phase 2b RewinD-LB clinical trial for neflamapimod, aimed at treating dementia with Lewy bodies. Topline data is expected in December 2024, and the trial design is optimized for success, potentially paving a clear path to market.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:27 pm

OPTX

Syntec Optics has secured $1.3M in orders for its datacom microlens array, with potential forecasted orders that could double the demand to $3.2M. The company plans to expand production and metrology to meet these orders in 2024 and early 2025.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:26 pm

GS

REGN

Regeneron Pharmaceuticals announced at the Goldman Sachs Conference that it anticipates releasing trial data for its obesity drug by 2025.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:23 pm

NAMS

NewAmsterdam Pharma (NASDAQ:NAMS) has announced the issuance of a new patent for obicetrapib by the USPTO, extending the patent term until July 2043. This development is significant for the company's portfolio of non-statin medicines targeting cardiovascular disease.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:21 pm

PCSA

Processa Pharmaceuticals announced positive results from its Phase 1b trial of a next-generation capecitabine for Stage III/IV GI cancer. The trial established the maximum tolerated dose and recommended Phase 2 dose range, with 66.7% of patients achieving progression-free survival ranging from 5 to 11 months.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:21 pm

HYMTF

TSLA

South Korean automakers Hyundai and Kia have achieved a record-high 11.2% share of the U.S. electric vehicle (EV) market in the first five months of 2024, up from 6.8% in 2023. Despite this growth, they still trail Tesla, which leads the market by 40.5 percentage points.

Portfolio Pulse from Anan Ashraf

June 11, 2024 | 12:20 pm

NTAP

NetApp (NASDAQ:NTAP) has appointed Mike Sakalas as Vice President of U.S. Enterprise Sales to drive growth and enhance customer success. Sakalas will report to Riccardo Di Blasio, Senior Vice President of North America Sales, and will focus on developing and executing NetApp's enterprise business strategy in the U.S.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:20 pm

MOLN

Molecular Partners shares are trading higher following the announcement of their lead Raido-DARPin therapy candidate MP0712, which targets DLL3.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:20 pm